NEW YORK, Oct 4 – PerkinElmer (NYSE: PKI) has subscribed to Incyte Genomics’ (Nasdaq: INCY) LifeSeq Gold gene sequence database for use in developing microarray-based gene expression analysis technology, the companies said Wednesday.
Under the terms of the deal, Incyte will offer NEN Life Science Products, a PerkinElmer subsidiary, full use of its proprietary cDNA clone sets. In exchange, Incyte will receive royalties from the sales of microarrays the company develops. Incyte has also agreed to offer its biological expertise to NEN in development of focused arrays that study specific diseases and disease pathways.
“We are pleased to expand our network of collaborators to include NEN, a proven leader in the microarray field,” Roy Whitfield, Incyte’s CEO, said in a statement. “We are continuing to broadly license our information enabling researchers worldwide to understand the molecular basis of disease, and expedite the development of new medicines.”
The companies did not disclose the financial terms of the agreement.
In the past two months, Incyte has signed similar partnerships with several other gene chip manufacturers.
On Tuesday Incyte said it had licensed two of its patents to American Home Products (AHP) so the company could create gene expression data using Affymetrix GeneChip arrays.
In August Incyte granted Motorola’s (NYSE: MOT) BioChip Systems unit the licensing rights to use Incyte’s LifeSeq Gold database to develop gene chips.
Additionally, on July 31 Incyte announced it had licensed its Easy-to-Spot pre-assembled set of non-proprietary human and mouse clones to Amersham Pharmacia Biotech, the life sciences business of Nycomed Amersham (LSE: NAM; NYSE: NYE), for use in its gene expression microarray products.
Incyte's shares were down 1, or 2.7 percent, at 36 1/2 in afternoon trading. PerkinElmer was off 5 3/16, or 5 percent, at 97 15/16.